Meeting
2022 ASCO Annual Meeting
A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305.
Authors
Athanassios Argiris
Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA
Athanassios Argiris , Yael Flamand , Panayiotis Savvides , Jennifer Maria Johnson , Shuli Li , Arlene A. Forastiere , Barbara Burtness
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6026)
DOI
10.1200/JCO.2022.40.16_suppl.6026
Abstract #
6026
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Clinical outcomes of patients with recurrent small cell lung cancer receiving third-line chemotherapy.
First Author: Koichi Saruwatari
Poster
2024 ASCO Annual Meeting
Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.
First Author: Zahra Hamedi
Poster
2022 ASCO Annual Meeting
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.
First Author: Gordon Taylor Moffat
Poster
2022 ASCO Annual Meeting
Taxanes plus cetuximab with or without platinum chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.
First Author: Khalil Saleh